Literature DB >> 1858696

Fluoxetine's effect on weight loss in obese subjects.

L L Darga1, L Carroll-Michals, S J Botsford, C P Lucas.   

Abstract

Forty-five obese subjects with a mean weight of 102.9 kg and a body mass index (in kg/m2) of 37.6 were randomly assigned to a fluoxetine-diet group (n = 23) or a placebo-diet group (n = 22) for 52 wk. At week 29, 14 subjects on fluoxetine who completed the study attained their maximum weight loss of 12.4 kg, an amount significantly greater than the maximum weight loss of 4.5 kg for the 16 on placebo who completed the study. The fluoxetine group's significantly greater mean weight loss continued through week 45. However, those on fluoxetine regained a mean of 4.2 kg from their lowest weight (P less than 0.001) whereas the placebo group did not. By the end of the study, each group weighed significantly less than they did at baseline (fluoxetine: -8.2 kg; placebo: -4.5 kg; P less than 0.05) although the difference between groups was no longer significant (P greater than 0.05). Several factors were considered as possible causes for the regain with fluoxetine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858696     DOI: 10.1093/ajcn/54.2.321

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  16 in total

Review 1.  A risk-benefit assessment of anti-obesity drugs.

Authors:  J Kolanowski
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

Review 2.  Antiobesity drugs: current and future issues.

Authors:  M Ammar Hatahet; Nikhil V Dhurandhar
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 3.  Depression and myocardial infarction. Implications for medical prognosis and options for treatment.

Authors:  T J Cleophas
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 4.  Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Emma J Boyland; Clare L Lawton; John E Blundell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Fluoxetine Modulates the Activity of Hypothalamic POMC Neurons via mTOR Signaling.

Authors:  Ilaria Barone; Riccardo Melani; Marco Mainardi; Gaia Scabia; Manuela Scali; Alessia Dattilo; Giovanni Ceccarini; Paolo Vitti; Ferruccio Santini; Lamberto Maffei; Tommaso Pizzorusso; Margherita Maffei
Journal:  Mol Neurobiol       Date:  2018-04-16       Impact factor: 5.590

Review 6.  Current concepts in the pharmacological management of obesity.

Authors:  P J Carek; L M Dickerson
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 7.  Bodyweight gain with atypical antipsychotics. A comparative review.

Authors:  T Wetterling
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

Review 8.  Pharmacotherapy for obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; John J McNeil
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Metabolic effects of fluoxetine in obese menopausal women.

Authors:  M Bondi; R Menozzi; M Bertolini; M G Venneri; G Del Rio
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

Review 10.  Psychotropic drugs in the treatment of obesity: what promise?

Authors:  Jose C Appolinario; João R Bueno; Walmir Coutinho
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.